Search | Clinical Trials Finder

Conditions: Chronic Granulomatous Disease, Inflammatory Bowel Disease
Interventions: Neocate Splash; Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Inflammatory Bowel Disease
Interventions: Filgotinib, Placebo, Standard of Care; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 21 Years to 65 Years · Male only
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 10
States / cities: San Diego, California • Lakewood Rch, Florida • Miami, Florida + 7 more

Conditions: Irritable Bowel Syndrome
Interventions: AST-120, Celphere® CP-305; Drug
Lead sponsor: Ocera Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 13
States / cities: Huntsville, Alabama • Sacramento, California • San Diego, California + 10 more

Conditions: Arthritis, Juvenile Rheumatoid, Crohn Disease
Interventions: somatropin [rDNA origin] for injection; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 5 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Interventions: Placebo, Rifaximin; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 35 Years to 72 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Crohn Disease
Interventions: Ozanimod, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 81
States / cities: Scottsdale, Arizona • La Jolla, California • Lancaster, California + 67 more

Conditions: Ulcerative Colitis
Interventions: Etrozulimab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 38
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 32 more

Conditions: Inflammatory Bowel Disease, Crohn's Disease
Interventions: Not listed
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Crohn's Disease, Inflammatory Bowel Diseases
Interventions: Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Crohn's; Biological
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Adenomatous Polyp, Crohn Disease, Familial Adenomatous Polyposis, Hereditary Intestinal Polyposis Syndrome, Recurrent Colon Cancer, Stage I Colon Cancer, Stage IIA Colon Cancer, Stage IIB Colon Cancer, Stage IIC Colon Cancer, Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer
Interventions: therapeutic laparoscopic surgery; Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Crohn Disease
Interventions: Vedolizumab, Adalimumab, Methotrexate; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 27
States / cities: Dothan, Alabama • Clearwater, Florida • Atlanta, Georgia + 24 more

Conditions: Crohn's Disease of Large Intestine, Malignant Neoplasm of Colon
Interventions: Obtaining bowel gas samples; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Ulcerative Colitis
Interventions: BT051 200 mg, BT051 800 mg, BT051 3200 mg, Matching Placebo; Drug
Lead sponsor: Adiso Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Rialto, California • Kissimmee, Florida

Conditions: Constipation Predominant Irritable Bowel Syndrome
Interventions: RDX5791; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 16
States / cities: San Diego, California • Jupiter, Florida • Pinellas Park, Florida + 13 more

Conditions: Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions: ergocalciferol, Cholecalciferol; Dietary Supplement
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 5 Years to 21 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Crohn's Disease, Inflammatory Bowel Disease
Interventions: Corticosteroid; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Crohn's Disease
Interventions: Mirikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 996 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 54
States / cities: Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 49 more

Conditions: Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions: Specimen sample; Diagnostic Test
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Colitis
Interventions: Enhanced Digital Care, Education; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 13 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 9
States / cities: Scottsdale, Arizona • San Diego, California • San Francisco, California + 6 more

Conditions: Constipation Predominant Irritable Bowel Syndrome
Interventions: Tenapanor, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 593 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 117
States / cities: Dothan, Alabama • Foley, Alabama • Huntsville, Alabama + 98 more

Conditions: Irritable Bowel Syndrome
Interventions: Dietary intervention; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Indianapolis, Indiana • Ann Arbor, Michigan

Conditions: Persian Gulf Syndrome
Interventions: Carnosine, Placebo; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 34 Years to 82 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Crohn Disease
Interventions: infliximab infusion; AZA placebo caps, infliximab (IFX) infusion; azathioprine (AZA) caps, infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Biological · Other · Drug
Lead sponsor: Centocor Ortho Biotech Services, L.L.C.; Industry
Eligibility: 21 Years to 99 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 51
States / cities: Birmingham, Alabama • Phoenix, Arizona • Orange, California + 48 more

Conditions: Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
Interventions: SPY001, SPY002, SPY003, Placebo; Drug · Other
Lead sponsor: Spyre Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 645 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 26
States / cities: Canoga Park, California • La Jolla, California • Lancaster, California + 23 more

Search by objective public record fields.

Elemental Diet for Treatment of Inflammatory Bowel Disease in Patients With Chronic Granulomatous Disease

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome

Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease

Gulf War Digestive Health Study

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors

OPERA Database - Crohn's Protocol

Beta-Hydroxybutyrate Feasibility Treating IBD

Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease

Triple Combination Therapy in High Risk Crohn's Disease (CD)

Evaluation of Ability to Detect Bowel Gas During Laparoscopic Right Colectomy With Intracorporeal Anastomosis

An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)

A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Vitamin D Levels in Children With IBD

Corticosteroid Dosage for Crohn's Disease Flare

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C

Comparing the Effectiveness of 2 Diets for Patients With Irritable Bowel Syndrome

Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI)

Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis